Freezing human milk is recommended to inactivate cytomegalovirus (CMV). A case of a preterm infant exclusively receiving frozen breast milk from his CMV seropositive mother showed that storage of breast milk for two months at −20°C did not prevent symptomatic postnatal CMV infection.
- CMV, cytomegalovirus
- BAL, bronchoalveolar lavage fluid
- PCR, polymerase chain reaction
- breast milk
Statistics from Altmetric.com
Breast milk is the main source of postnatal transmission of cytomegalovirus (CMV) to preterm infants, which in turn can cause severe illness.1–7 Various methods of virus inactivation in human milk have been described.8,9,10,11 Freezing human milk at −20°C for several days has been found to reduce or destroy viral infectivity in vitro. However, a certain level of infectivity remained, and there have been conflicting reports about the effectiveness of freeze-thawing. A range from 99% reduction of virus load after three days at −20°C9 to still detectable infectivity after 10 days at −15°C11 and after 10 days at −20°C in CMV-spiked milk has been reported, whereas in naturally infectious milk specimens, CMV was completely inactivated after storage at −20°C for seven days.8 On the other hand, no other treatment of human milk does less harm to its nutritional and immunological components than freeze-thawing.12,13 Because of the widespread and recommended14,15 use of freeze-thawing as a method to minimise infectious agents in human milk,16 we wanted to protect a preterm infant with high risk of postnatal CMV infection from breast milk by exclusive administration of freeze-thawed human milk.
PATIENT AND METHODS
A male preterm infant of 28+1 weeks gestational age was born by caesarean section because of intrauterine growth retardation with increasingly pathological Doppler results of umbilical cord and fetal vessels. The Apgar score was 8/9/9 after one, five, and 10 minutes respectively, and arterial cord blood pH was 7.32. The 36 year old mother of Brazilian origin was CMV IgG seropositive. Therefore her own sequentially frozen breast milk samples were used exclusively from the start of feeding at the second day of life.
CMV analysis of breast milk, blood, urine, and bronchoalveolar lavage fluid (BAL) of the infant was performed as described.1 After being thawed, the milk whey fraction was prepared.17 Aliquots of milk whey were used immediately for detection of virus infectivity and viral DNA load.18 To assess the viral load, micro cultures consisting of freshly prepared monolayers (four hours after seeding) of human foreskin fibroblasts (2.5 × 104 in 100 μl minimum essential medium/10% fetal calf serum per well) were used as previously described.18 After DNA isolation from milk whey, viral DNA was amplified by nested polymerase chain reaction (PCR) using primer sequences of the CMV immediate early exon 4 region.17 Quantitative PCR of DNA from milk whey was performed using the Cobas Amplicor CMV Monitor test (Roche Molecular Biochemicals, Mannheim, Germany).18
For the description of DNA and virus decrease, logarithms of the measurements were fitted by linear regressions that correspond to an exponential decline after back transformation. For the quantitative PCR analysis, the geometric mean was estimated.
The study was approved by the ethics committee of the Medical Faculty of the University of Tübingen. Informed consent was obtained from the mother to test her milk.
The premature infant showed distinct growth retardation at birth (birth weight 490 g, length 28 cm, head circumference 21 cm, all values below the 3rd centile) with insufficient weight gain during the following weeks (1000 g after 10 weeks) despite full enteral feeding. Hepatopathy with an enlarged liver, rising liver enzyme activity, and increasing bilirubin concentrations gradually developed, strongly suggesting congenital liver disease. An extensive search for an infectious, metabolic, or genetic cause was inconclusive. Furthermore, a persisting thrombocytopenia and anaemia necessitated recurrent transfusions. All blood products transfused were CMV seronegative and inline filtered. CMV monitoring showed no infection during the first 16 weeks of life. At day 108, the infant’s clinical condition deteriorated rapidly to a sepsis-like status with severe episodes of apnoea requiring reintubation (table 1).
Monitoring for CMV revealed positive qualitative PCR results for leucocytes, plasma, urine, and BAL (table 2), yet the bacterial blood cultures remained negative. In addition, viral isolates were obtained subsequently on day 111 from urine and BAL (table 2).
Antiviral therapy was not given. After six days, extubation was possible, and the condition was stable. However, the underlying pathology worsened, and the infant finally died on day 158 from respiratory failure due to the extreme hepatosplenomegaly. Post-mortem examination showed an idiopathic intrahepatic biliary duct hypoplasia.
Retrospective analysis of frozen breast milk samples from the mother of this preterm infant, given on the day of clinical deterioration and later, revealed the presence of infectious virus with a background of very high CMV DNA load. In the further course of lactation, both the viral DNA load and the amount of infectious virus decreased rapidly (fig 1). The predicted DNA decrease provides a very close fit to the observed results. The exponential decline had a daily reduction rate of the DNA load of 14%—that is, a half life of 4.6 days. Owing to the vast abundance of breast milk in this case, the infant received freeze-thawed milk from day 43 when he was 108 days old, resulting in a freezing time of 65 days. CMV transmission probably occurred between day 72 (last CMV negative urine sample) and day 108 (beginning of the symptomatology). As genotyping using human CMV UL10–UL13 glycoprotein gene sequences1 revealed, the viral strains isolated from breast milk and urine of the infant were identical (data not shown).
This case report provides strong evidence that freezing does not inactivate CMV in breast milk under clinical conditions and does not prevent CMV transmission. The fact that CMV-containing breast milk could still lead to a clinically relevant CMV infection of a preterm infant with idiopathic intrahepatic biliary duct hypoplasia after more than two months storage at −20°C has not been previously reported. Even after storage for one year at −20°C and three freeze-thawing cycles, we were able to isolate infectious virus from the whey fraction of these breast milk samples (data not shown). Genotyping of viral strains isolated from breast milk and urine1 showed that breast feeding was the only source of virus transmission to the infant. Recent publications4,5,15 report that, despite the exclusive or predominant use of frozen breast milk, there can still be CMV transmission with apparent clinical symptoms.3
We can only speculate about the possible effect of the underlying disease in our index patient on the facilitation of the CMV infection and disease. However, he had a high risk of acquiring a postnatal CMV infection from untreated breast milk.7 The exponential decline in DNA load led to the speculation that a preceding increase was also exponential with a sharp peak load, which has been confirmed.18,19 Owing to the wide gap between the postnatal age of the preterm infant and the true age of the breast milk he received, and the reported unimodal dynamics of DNAlactia and virolactia during lactation,18 we must assume that, for many days before day 108 post partum, breast milk with a very high CMV load was fed to this infant. Unfortunately, we did not monitor the breast milk prospectively. Using both native milk from seropositive mothers and artificially infected milk from seronegative mothers, we recently showed that, during maximal virus excretion, CMV viral load can only be reduced but not eliminated by freeze-thawing.20 When aiming to protect a population at risk from the hazards of postnatal CMV transmission through breast milk, freezing cannot be recommended.
We thank Andrea Baumeister and Elfriede Mikeler for their excellent technical assistance.
Funding: this study was supported by a grant from Deutsche Forschungsgemeinschaft (DFG), Bonn, Germany (DFG HA 1559/2-1).
Competing interests: none declared
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.